Tempest Therapeutics Inc

Tempest Therapeutics maintains a strong liquidity position, with $32.33 million in cash and equivalents, significantly exceeding its total liabilities of $23.75 million, resulting in a current ratio of 3.13. The company's price-to-book ratio of 1.45 suggests that the market values the firm at a moderate premium to its book value, while the debt-to-equity ratio of 0.51 indicates a relatively conservative capital structure. The company is currently unprofitable, with a net loss of $7.90 million and an operating loss of $7.97 million, resulting in a negative return on equity of -38.31% and a negative return on assets of -17.81%. These metrics fall below the typical performance benchmarks for the biotechnology and medical research industry, which often prioritize long-term R&D investment over short-term profitability. Tempest Therapeutics does not disclose segment or geographic revenue breakdowns in the available data, making it difficult to assess the concentration of its revenue streams or geographic exposure. This lack of transparency may limit the ability to evaluate the company's diversification and resilience to regional or market-specific risks. The company's growth trajectory is not clearly defined in the available data, as no specific revenue growth rates or forward-looking guidance are provided. Analysts have assigned a mean price target of $11.00, significantly higher than the current market price of $2.09, but the absence of a strong-buy recommendation suggests limited near-term optimism. Risk factors for Tempest Therapeutics include its current unprofitability and negative cash flow from operations, which could pressure liquidity if cash burn accelerates. However, the company has no immediate filing-based liquidity or dilution flags, and its dilution risk is assessed as low. Recent events include the publication of the latest financial data, which shows continued losses and negative operating cash flow. No recent filings or transcripts are available to provide additional insight into the company's strategic direction or operational progress.